Immunohistochemical study of the receptors for retinoic acid in prostatic adenocarcinoma.
Retinoids play an important role in regulating cellular proliferation and differentiation. Although their effects are mediated by retinoic acid receptors (RARs) and retinoid X receptors (RXRs), limited information is available about the expression of RARs and RXRs in prostatic adenocarcinoma. We intended in this study to elucidate further the participation of those receptors in tumor progression of human prostate. The immunohistochemical expression of RARs and RXRs proteins was studied using paraffin-embedded archival tissues obtained from patients with and without neoadjuvant hormonal therapies for prostatic adenocarcinoma. The immunoreactivity against RAR-alpha, RAR-gamma, RXR-alpha and RXR-gamma were detected in many, if not all, prostatic adenocarcinoma cells of the cases without and with neoadjuvant hormonal therapy, whereas less expression of both RAR-beta and RXR-beta were identified. Positively stained adenocarcinoma cells with RAR-beta and RXR-beta were found to be decreased in the cases with neoadjuvant therapy. In addition, the specimens showing positive immunoreaction of RAR-beta were limited to the cases of moderately- and poorly-differentiated but not well-differentiated, adenocarcinomas. We first demonstrated the expression of RARs and RXRs proteins in prostatic adenocarcinoma using subtype-specific antibodies. Immunohistochemistry using those antibodies might give an indication of susceptibility of the patients to retinoid therapy as a possible treatment of prostatic adenocarcinoma.